PDF herunterladen
Horm Metab Res 2014; 46(09): 597-602
DOI: 10.1055/s-0034-1382053
Review
© Georg Thieme Verlag KG Stuttgart · New York

IP-10 in Autoimmune Thyroiditis

I. Ruffilli
1   Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
S. M. Ferrari
1   Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
M. Colaci
2   Department of Medical, Surgical, Maternal, Pediatric and Adult Sciences, University of Modena and Reggio Emilia, Modena, Italy
,
C. Ferri
2   Department of Medical, Surgical, Maternal, Pediatric and Adult Sciences, University of Modena and Reggio Emilia, Modena, Italy
,
P. Fallahi
1   Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
,
A. Antonelli
1   Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 03. April 2014

accepted 27. Mai 2014

Publikationsdatum:
30. Juni 2014 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

The interferon-γ-inducible protein 10 (IP-10) was initially identified as a chemokine that is induced by interferon (IFN)-γ. IP-10 exerts its function through binding to chemokine (C-X-C motif) receptor 3 (CXCR3). IP-10 and its receptor, CXCR3, appear to contribute to the pathogenesis of many autoimmune diseases, organ specific (such as type 1 diabetes, Graves’ disease and ophthalmopathy), or systemic (such as systemic lupus erythematosus, mixed cryoglobulinemia, Sjogren syndrome, or systemic sclerosis). The secretion of IP-10 by (CD)4+, CD8+, and natural killer is dependent on IFN-γ. Under the influence of IFN-γ, IP-10 is secreted by thyrocytes. Determination of high level of IP-10 in peripheral fluids is therefore a marker of a T helper 1 orientated immune response. High levels of circulating IP-10, have been shown in patients with autoimmune thyroiditis (AT). Among patients with AT, IP-10 levels were significantly higher in those with a hypoechoic ultrasonographic pattern, which is a sign of a more severe lympho-monocytic infiltration, and in those with hypothyroidism. For these reasons, it has been postulated that IP-10 could be a marker of a stronger and more aggressive inflammatory response in the thyroid, subsequently leading to thyroid destruction and hypothyroidism. Further studies are needed to investigate whether IP-10 is a novel therapeutic target in AT.

Key words

thyroid autoimmunity - CXCL10 - CXCR3 - thyroid autoantibodies
 

  • References

  • 1 Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25: 787-820
    CrossrefPubMedGoogle Scholar
  • 2 Ohmori Y, Hamilton TA. The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J Immunol 1995; 154: 5235-5244
    PubMedGoogle Scholar
  • 3 Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999; 163: 6236-6243
    PubMedGoogle Scholar
  • 4 Dillman 3rd JF, McGary KL, Schlager JJ. An inhibitor of p38 MAP kinase downregulates cytokine release induced by sulfur mustard exposure in human epidermal keratinocytes. Toxicol In Vitro 2004; 18: 593-599
    CrossrefPubMedGoogle Scholar
  • 5 Ohmori Y, Hamilton TA. Cell type and stimulus specific regulation of chemokine gene expression. Biochem Biophys Res Commun 1994; 198: 590-596
    CrossrefPubMedGoogle Scholar
  • 6 Ge MQ, Ho AW, Tang Y, Wong KH, Chua BY, Gasser S, Kemeny DM. NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-gamma and perforin-dependent mechanisms. J Immunol 2012; 189: 2099-2109
    CrossrefPubMedGoogle Scholar
  • 7 Moodley K, Angel CE, Glass M, Graham ES. Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. J Neurosci Methods 2011; 200: 173-180
    CrossrefPubMedGoogle Scholar
  • 8 Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014; 13: 272-280
    CrossrefPubMedGoogle Scholar
  • 9 Jinquan T, Jing C, Jacobi HH, Reimert CM, Millner A, Quan S, Hansen JB, Dissing S, Malling HJ, Skov PS, Poulsen LK. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. J Immunol 2000; 165: 1548-1556
    CrossrefPubMedGoogle Scholar
  • 10 Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993; 177: 1809-1814
    CrossrefPubMedGoogle Scholar
  • 11 Engel MA, Neurath MF. Anticancer properties of the IL-12 family – focus on colorectal cancer. Curr Med Chem 2010; 17: 3303-3308
    CrossrefPubMedGoogle Scholar
  • 12 Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008; 8: 18-23
    CrossrefPubMedGoogle Scholar
  • 13 Antonelli A, Rotondi M, Fallahi P, Ferrari SM, Paolicchi A, Romagnani P, Serio M, Ferrannini E. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006; 34: 32-38
    CrossrefPubMedGoogle Scholar
  • 14 Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves’ disease or toxic nodular goiter. J Clin Endocrinol Metab 2007; 92: 1485-1490
    CrossrefPubMedGoogle Scholar
  • 15 Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009; 94: 1803-1809
    CrossrefPubMedGoogle Scholar
  • 16 Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Okamoto H, Ferrannini E. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves’ disease. Clin Exp Immunol 2001; 126: 426-431
    CrossrefPubMedGoogle Scholar
  • 17 Antonelli A, Baj G, Marchetti P, Fallahi P, Surico N, Pupilli C, Malavasi F, Ferrannini E. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001; 50: 985-991
    CrossrefPubMedGoogle Scholar
  • 18 Antonelli A, Tuomi T, Nannipieri M, Fallahi P, Nesti C, Okamoto H, Groop L, Ferrannini E. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002; 45: 1298-1306
    CrossrefPubMedGoogle Scholar
  • 19 Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d’Annunzio G, Lorini R, Vanelli M, Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 2008; 25: 1349-1353
    PubMedGoogle Scholar
  • 20 Cossu A, Ferrannini E, Fallahi P, Antonelli A, Sechi LA. Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis’s MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. Cytokine 2013; 61: 337-339
    CrossrefPubMedGoogle Scholar
  • 21 Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev 2014; 25: 57-65
    CrossrefPubMedGoogle Scholar
  • 22 Lee EY, Lee ZH, Song YW. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2013; 12: 554-557
    CrossrefPubMedGoogle Scholar
  • 23 Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173: 310-317
    CrossrefPubMedGoogle Scholar
  • 24 Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F, Ferrannini E. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis – a longitudinal study. Rheumatology (Oxford) 2008; 47: 45-49
    CrossrefPubMedGoogle Scholar
  • 25 Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Ferrannini E. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008; 35: 1809-1811
    PubMedGoogle Scholar
  • 26 Antonelli A, Delle Sedie A, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol 2006; 33: 2026-2028
    PubMedGoogle Scholar
  • 27 Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 2008; 41: 537-542
    CrossrefPubMedGoogle Scholar
  • 28 Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol 2009; 27: 22-27
    PubMedGoogle Scholar
  • 29 Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006; 130: 526-532
    CrossrefPubMedGoogle Scholar
  • 30 Su R, Nguyen ML, Agarwal MR, Kirby C, Nguyen CP, Ramstein J, Darnell EP, Gomez AD, Ho M, Woodruff PG, Koth LL. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res 2013; 14: 121
    CrossrefPubMedGoogle Scholar
  • 31 Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longombardo G, Fadda P, Pampana A, Maccheroni M, Ferrannini E. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004; 97: 499-506
    CrossrefPubMedGoogle Scholar
  • 32 Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008; 103: 2488-2494
    CrossrefPubMedGoogle Scholar
  • 33 Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007; 39 (Suppl. 01) S13-S21
    CrossrefPubMedGoogle Scholar
  • 34 Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Giunti M, Pileri SA, Zignego AL. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007; 7: 114-120
    CrossrefPubMedGoogle Scholar
  • 35 Tozzoli R, Barzilai O, Ram M, Villalta D, Bizzaro N, Sherer Y, Shoenfeld Y. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008; 8: 112-115
    CrossrefPubMedGoogle Scholar
  • 36 Burek CL, Rose NR. Autoimmune thyroiditis and ROS. Autoimmun Rev 2008; 7: 530-537
    Google Scholar
  • 37 McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev 2014; 35: 59-105
    CrossrefPubMedGoogle Scholar
  • 38 Guarneri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes 2007; 14: 398-409
    CrossrefPubMedGoogle Scholar
  • 39 Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol 2014; 9: 147-156
    CrossrefPubMedGoogle Scholar
  • 40 McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012; 42: 252-265
    Google Scholar
  • 41 Benvenga S, Trimarchi F. Changed presentation of Hashimoto’s thyroiditis in North-Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid 2008; 18: 429-441
    CrossrefPubMedGoogle Scholar
  • 42 Rizzo M, Rossi RT, Bonaffini O, Scisca C, Altavilla G, Calbo L, Rosanò A, Sindoni A, Trimarchi F, Benvenga S. Increased annual frequency of Hashimoto’s thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris) 2010; 71: 525-534
    CrossrefPubMedGoogle Scholar
  • 43 Weetman AP. Cellular immune responses in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2004; 61: 405-413
    Google Scholar
  • 44 Nanba T, Watanabe M, Inoue N, Iwatani Y. Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease. Thyroid 2009; 19: 495-501
    CrossrefPubMedGoogle Scholar
  • 45 Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, Sánchez-Madrid F, González-Amaro R, Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2010; 95: 953-962
    Google Scholar
  • 46 Li D, Cai W, Gu R, Zhang Y, Zhang H, Tang K, Xu P, Katirai F, Shi W, Wang L, Huang T, Huang B. Th17 cell plays a role in the pathogenesis of Hashimoto’s thyroiditis in patients. Clin Immunol 2013; 149: 411-420
    Google Scholar
  • 47 García-López MA, Sancho D, Sánchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001; 86: 5008-5016
    CrossrefPubMedGoogle Scholar
  • 48 Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003; 59: 207-213
    CrossrefPubMedGoogle Scholar
  • 49 Kimura H, Kimura M, Rose NR, Caturegli P. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto’s thyroiditis. Exp Mol Pathol 2004; 77: 161-167
    CrossrefPubMedGoogle Scholar
  • 50 Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004; 89: 5496-5499
    CrossrefPubMedGoogle Scholar
  • 51 Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005; 152: 171-177
    CrossrefPubMedGoogle Scholar
  • 52 Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, Galetta F, Ferrannini E. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008; 42: 137-143
    CrossrefPubMedGoogle Scholar
  • 53 Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Carpi A, Nicolini A, Ferrannini E. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 2008; 57: 1270-1277
    CrossrefPubMedGoogle Scholar
  • 54 Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Pampana A, Panicucci E, Carpi A, Nicolini A, Ferrannini E. CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine Res 2009; 29: 345-351
    CrossrefPubMedGoogle Scholar
  • 55 Antonelli A, Ferri C, Ferrari SM, De Marco S, Di Domenicantonio A, Centanni M, Pupilli C, Villa E, Menichetti F, Fallahi P. Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. J Interferon Cytokine Res 2010; 30: 835-842
    CrossrefPubMedGoogle Scholar
  • 56 Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009; 5: 26-34
    CrossrefPubMedGoogle Scholar
  • 57 Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves’ disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154: 651-658
    CrossrefPubMedGoogle Scholar
  • 58 Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, Miccoli M, Benvenga S, Paolicchi A, Ferrannini E, Fallahi P. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 2011; 55: 288-293
    CrossrefPubMedGoogle Scholar
  • 59 Antonelli A, Fallahi P, Ferrari SM, Sebastiani M, Manfredi A, Mazzi V, Fabiani S, Centanni M, Marchi S, Ferri C. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2012; 22: 659-667
    CrossrefPubMedGoogle Scholar
  • 60 Antonelli A, Ferri C, Ferrari SM, Frascerra S, Ruffilli I, Caponi L, Ulisse S, Miccoli M, Miccoli P, Fallahi P. High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10. J Interferon Cytokine Res 2012; 32: 74-80
    CrossrefPubMedGoogle Scholar
  • 61 Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89: 207-215
    CrossrefPubMedGoogle Scholar
  • 62 Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006; 91: 614-620
    CrossrefPubMedGoogle Scholar
  • 63 Rotondi M, Coperchini F, Pignatti P, Sideri R, Groppelli G, Leporati P, La Manna L, Magri F, Mariotti S, Chiovato L. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?. J Clin Endocrinol Metab 2013; 98: 308-313
    CrossrefPubMedGoogle Scholar
  • 64 Benvenga S. On the association between Hashimoto’s thyroiditis and papillary thyroid carcinoma: looking 100 years back and, hopefully, fewer years ahead to sort out this association. Thyroid 2013; 23: 1180-1181
    CrossrefPubMedGoogle Scholar
  • 65 Jankovic B, Le KT, Hershman JM. Clinical Review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation?. J Clin Endocrinol Metab 2013; 98: 474-482
    CrossrefPubMedGoogle Scholar
  • 66 Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L, Pinchera A, Vitti P. Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with l-thyroxine. Endocr Relat Cancer 2011; 18: 429-437
    CrossrefPubMedGoogle Scholar
  • 67 Antonelli A, Ferri C, Fallahi P, Nesti C, Zignego AL, Maccheroni M. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol 2002; 20: 693-696
    PubMedGoogle Scholar
  • 68 Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, Marchi S, Ferrannini E. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007; 17: 447-451
    CrossrefPubMedGoogle Scholar
  • 69 Antonelli A, Miccoli P, Derzhitski VE, Panasiuk G, Solovieva N, Baschieri L. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg 1996; 20: 867-871
    CrossrefPubMedGoogle Scholar
  • 70 Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M, Miccoli P. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother 2008; 62: 559-563
    CrossrefPubMedGoogle Scholar
  • 71 Neri S, Boraschi P, Antonelli A, Falaschi F, Baschieri L. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. Am J Ind Med 1996; 30: 588-595
    CrossrefPubMedGoogle Scholar
  • 72 Spinelli C, Bertocchini A, Antonelli A, Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients<or=16 years old. J Pediatr Surg 2004; 39: 1500-1505
    CrossrefPubMedGoogle Scholar
  • 73 Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115: 1068-1081
    CrossrefPubMedGoogle Scholar
  • 74 Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F, Orlando C, Miccoli P. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer 2009; 16: 1299-1311
    CrossrefPubMedGoogle Scholar
  • 75 Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, Rossi FW, Basolo F, Ugolini C, de Paulis A, Santoro M, Marone G. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 2010; 29: 6203-6215
    CrossrefPubMedGoogle Scholar
  • 76 Proudfoot AE, Power CA, Rommel C, Wells TN. Strategies for chemokine antagonists as therapeutics. Semin Immunol 2003; 15: 57-65
    CrossrefPubMedGoogle Scholar
  • 77 Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, Tonnel AB, Trottein F. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001; 31: 2857-2865
    CrossrefPubMedGoogle Scholar
  • 78 Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000; 164: 6503-6508
    CrossrefPubMedGoogle Scholar
  • 79 Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005; 11: 244-252
    CrossrefPubMedGoogle Scholar
  • 80 Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, Salvi M, Ferrannini E. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011; 60: 277-283
    CrossrefPubMedGoogle Scholar
  • 81 Oliveira AC, Bertollo CM, Rocha LT, Nascimento Jr EB, Costa KA, Coelho MM. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 2007; 561: 194-201
    CrossrefPubMedGoogle Scholar
  • 82 Spencer NF, Poynter ME, Im SY, Daynes RA. Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol 1997; 9: 1581-1588
    CrossrefPubMedGoogle Scholar
  • 83 Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, Lytle C, Straus DS. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterology 2007; 133: 108-123
    CrossrefPubMedGoogle Scholar
  • 84 Antonelli A, Ferrari SM, Frascerra S, Corrado A, Pupilli C, Bernini G, Benvenga S, Ferrannini E, Fallahi P. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves’ disease. Exp Cell Res 2011; 317: 1527-1533
    CrossrefPubMedGoogle Scholar
  • 85 Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048-32054
    CrossrefPubMedGoogle Scholar
  • 86 Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759-763
    CrossrefPubMedGoogle Scholar